Seeking Alpha
Profile| Send Message|
( followers)  

Today's Journal of the American Medical Association [JAMA] has an article demonstrating that Trexima, a migraine treatment combining Imitrex and naproxen sodium, relieves migraine headaches significantly more effectively than either drug alone, according to two separate studies.gsk-pozn The combination therapy is produced by GlaxoSmithKline and Pozen Inc.; Pozen's shares jumped nearly 9% in after hours trading on the news. Trexima was found to stop moderate to severe migraines in 65% of cases, versus just 55% effective relief for Imitrex alone, 44% for naproxen sodium alone and just 28% for the placebo. Some doctors have known combination therapy was more effective for some time; according to neurologist Richard Lipton, "We've used combination therapy for a long time... these two studies provide really solid evidence that the combination treatment is rational and provides better outcomes."

Sources: Press Release, Washington Post, Bloomberg, Reuters,
Commentary: GlaxoSmithKline, Like Other Pharmas, Ignored in Good Drug PressGlaxo's Q4 Earnings Mostly In-line, Shares Up on '07 Prospects
Stocks/ETFs to watch: GlaxoSmithKline (NYSE:GSK), Pozen Inc. (NASDAQ:POZN). Competitors: Pfizer (NYSE:PFE), Merck (NYSE:MRK), Novartis (NYSE:NVS), Sanofi-Aventis (NYSE:SNY). ETFs: iShares S&P Global Healthcare (NYSEARCA:IXJ)

Seeking Alpha's news briefs are combined into a pre-market summary called Wall Street Breakfast. Get Wall Street Breakfast by email -- it's free and takes only seconds to sign up.

Source: JAMA: GlaxoSmithKline-Pozen Combination Treatment Increases Anti-Migraine Effectiveness